Apis Capital Advisors LLC Lowers Stake in Abivax SA Sponsored ADR $ABVX

Apis Capital Advisors LLC lessened its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 15.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 89,000 shares of the company’s stock after selling 16,400 shares during the period. Abivax makes up 2.1% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 18th largest holding. Apis Capital Advisors LLC owned 0.11% of Abivax worth $12,002,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its stake in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after acquiring an additional 344 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Abivax in the 4th quarter worth $61,000. WPG Advisers LLC lifted its stake in shares of Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after acquiring an additional 253 shares during the period. Finally, Union Bancaire Privee UBP SA acquired a new stake in shares of Abivax in the 4th quarter worth $67,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Up 2.7%

Shares of NASDAQ ABVX opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a 52 week low of $5.69 and a 52 week high of $148.83. The firm has a 50-day moving average price of $114.81 and a 200 day moving average price of $118.49. The stock has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.22 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to analyst estimates of $0.40 million. Equities research analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ABVX. Citigroup restated an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Barclays raised their target price on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Finally, Wolfe Research set a $136.00 price objective on shares of Abivax in a research note on Wednesday, June 3rd. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $130.08.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.